Stocks That Hit 52-Week Lows On Monday
Before 10 a.m. ET Monday, 63 stocks made new 52-week lows.
Stocks That Hit 52-Week Lows On Friday
Before 10 a.m. ET Friday, 51 stocks hit new 52-week lows.
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
Exicure Provides Interim Results from Ongoing Phase 1b/2 Clinical Trial of Cavrotolimod
Exicure, Inc. (NASDAQ:XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, is providing an update on the Phase 1b/2 clinical trial of cavrotolimod
61 Biggest Movers From Yesterday
Gainers
Ever-Glory International Group, Inc. (NASDAQ: EVK) shares climbed 124.8% to close at $5.08 on Monday after the company announced a $5 million stock repurchase program.
Mid-Afternoon Market Update: Nasdaq Gains 50 Points; Marin Software Shares Plummet
Toward the end of trading Monday, the Dow traded up 0.02% to 34,941.69 while the NASDAQ rose 0.37% to 14,727.42. The S&P also rose, gaining 0.10% to 4,399.45.
Mid-Day Market Update: Crude Oil Down 2.5%; Exicure Shares Spike Higher
Midway through trading Monday, the Dow traded up 0.35% to 35,058.26 while the NASDAQ rose 0.52% to 14,748.83. The S&P also rose, gaining 0.39% to 4,412.29.
40 Stocks Moving In Monday’s Mid-Day Session
Gainers
Ever-Glory International Group, Inc. (NASDAQ: EVK) shares jumped 133% to $5.27 after the company announced a $5 million stock repurchase program.
Exicure Stock Surges On Over $1B Option Licensing Pact With Ipsen For Rare Neurodegenerative Disorders
Ipsen SA (OTC:IPSEY) and Exicure Inc (NASDAQ:XCUR) have collaborated to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational treatments…
21 Stocks Moving in Monday’s Pre-Market Session
Gainers
Exicure, Inc. (NASDAQ: XCUR) shares rose 41.5% to $1.91 in pre-market trading. Ipsen and Exicure signed an exclusive collaboration agreement to research, develop, and commercialize novel Spherical Nucleic Acids targeting rare neurodegenerative disorders.